Kisspeptin

Neuropeptide. Research verification: Yes (TGA pending). 1 human study record(s) in the FitClinicMD studies database.

GOALS · Hormone optimization / menopause / low T · Sexual function

FDA status

Not approved.

Compounding (503A/503B)

Kisspeptin-10: 503A Category 2 (Sep 29 2023)

DEA

Not controlled.

WADA (sport)

S2.2.1 Testosterone-stimulating peptides in males (CG, LH, GnRH/gonadorelin & agonist analogues, kisspeptin & agonist analogues)

Mechanism

KISS1R → GnRH.

Human evidence · 1

Kisspeptin-54 IVF trigger in high OHSS risk women, n=60. Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy.

2015RCTn=60PMID 26192876 →

Reference only. This page summarizes publicly available regulatory and research information about Kisspeptin. It is not a prescription, an endorsement, or an offer to dispense, and regulatory status can change. Clinicians should verify current status before prescribing or compounding.

Related compounds

● TIER 1GRADE A

Gonadorelin & GnRH analogs

GnRH agonists (leuprolide, triptorelin, goserelin) cause downregulation; antagonists (degarelix, relugolix, elagolix) block directly.

Open profile →

● TIER 1GRADE A

hCG

LH-receptor agonist.

Open profile →

● TIER 2GRADE B

Anastrozole & other AIs

Block aromatase.

Open profile →